American Heart Journal
Volume 159, Issue 2 , Pages 284-291.e1 , February 2010

Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry)

Received 23 July 2009 ,Accepted 18 November 2009.

References 

  1. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293:2126–2130
  2. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA. 2007;297:2001–2009
  3. de la Torre-Hernández JM, Alfonso F, Hernández F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA. J Am Coll Cardiol. 2008;51:986–990
  4. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  5. Lee SW, Park SW, Hong MK, et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol. 2005;95:859–862
  6. Lee BK, Lee SW, Park SW, et al. Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol. 2007;100:610–614
  7. Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005;46:1833–1837
  8. Ota H, Eto M, Ako J, et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation. J Am Coll Cardiol. 2009;53:2298–2305
  9. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006;152:627–635
  10. Robins J, Hernan M, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550–560
  11. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354–362
  12. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001–2015
  13. Jeong YH, Lee SW, Choi BR, et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity. J Am Coll Cardiol. 2009;53:1101–1109
  14. Ryningen A, Jensen BO, Holmsen H. Elevation of cyclic AMP decreases phosphoinositide turnover and inhibits thrombin-induced secretion in human platelets. Biochem Biophys Acta. 1998;1394:235–248
  15. Defreyn G, Gachet C, Savi P, et al. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. Thromb Haemost. 1991;65:186–190
  16. Hiratsuka M, Hinai Y, Sasaki T, et al. Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos. 2007;35:1730–1732
  17. Lee JH, Oh GT, Park SY, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 2005;313:502–509
  18. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: the DECLARE-DIABETES Trial. J Am Coll Cardiol. 2008;51:1181–1187
  19. Kwon SU, Cho YJ, Koo JS, et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36:782–786
  20. Brar SS, Kim J, Brar SK, et al. Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. J Am Coll Cardiol. 2008;51:2220–2227
  21. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  22. Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes. Am Heart J. 2009;157:733–739
  23. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. Vasc Surg. 2003;38:710–713
  24. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005;6:3–11

PII: S0002-8703(09)00894-1

doi: 10.1016/j.ahj.2009.11.014

American Heart Journal
Volume 159, Issue 2 , Pages 284-291.e1 , February 2010

Article Tools

* Image Usage & Resolution